These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27377717)

  • 1. Pharmacogenomic and personalized approaches to tackle nonalcoholic fatty liver disease.
    Lorbek G; Urlep Ž; Rozman D
    Pharmacogenomics; 2016 Jul; 17(11):1273-1288. PubMed ID: 27377717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized therapy when tackling nonalcoholic fatty liver disease: a focus on sex, genes, and drugs.
    Skubic C; Drakulić Ž; Rozman D
    Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):831-841. PubMed ID: 29969922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review.
    Severson TJ; Besur S; Bonkovsky HL
    World J Gastroenterol; 2016 Aug; 22(29):6742-56. PubMed ID: 27547017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2.
    Anstee QM; Day CP
    Semin Liver Dis; 2015 Aug; 35(3):270-90. PubMed ID: 26378644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic predisposition in nonalcoholic fatty liver disease.
    Sookoian S; Pirola CJ
    Clin Mol Hepatol; 2017 Mar; 23(1):1-12. PubMed ID: 28268262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The genetic backgrounds in nonalcoholic fatty liver disease.
    Seko Y; Yamaguchi K; Itoh Y
    Clin J Gastroenterol; 2018 Apr; 11(2):97-102. PubMed ID: 29492830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan.
    Akuta N; Kawamura Y; Arase Y; Suzuki F; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Ikeda K; Kumada H
    Gut Liver; 2016 May; 10(3):437-45. PubMed ID: 26610348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
    Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
    Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.
    Chen LZ; Xin YN; Geng N; Jiang M; Zhang DD; Xuan SY
    World J Gastroenterol; 2015 Jan; 21(3):794-802. PubMed ID: 25624712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic Fatty Liver Disease and Metabolic Syndrome.
    Kim D; Touros A; Kim WR
    Clin Liver Dis; 2018 Feb; 22(1):133-140. PubMed ID: 29128053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetics of Nonalcoholic Fatty Liver Disease: A 2018 Update.
    Valenti LVC; Baselli GA
    Curr Pharm Des; 2018; 24(38):4566-4573. PubMed ID: 30659533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetics and Epigenetics in the Clinic: Precision Medicine in the Management of Fatty Liver Disease.
    Cespiati A; Youngson NA; Tourna A; Valenti L
    Curr Pharm Des; 2020; 26(10):998-1009. PubMed ID: 31969087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical-morphological parallels of the PNPLA3 gene polymorphism in patients with nonalcoholic fatty liver disease.
    Tikhomirova AS; Kislyakov VA; Baykova IE; Nikitin IG
    Ter Arkh; 2018 Feb; 90(2):85-88. PubMed ID: 30701779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
    Krawczyk M; Stachowska E; Milkiewicz P; Lammert F; Milkiewicz M
    Digestion; 2016; 93(2):139-48. PubMed ID: 26745555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Genetics of Pediatric Nonalcoholic Fatty Liver Disease.
    Goyal NP; Schwimmer JB
    Clin Liver Dis; 2018 Feb; 22(1):59-71. PubMed ID: 29128061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
    Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
    J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis of non-alcoholic fatty liver disease (NAFLD).
    Yki-Järvinen H
    Diabetologia; 2016 Jun; 59(6):1104-11. PubMed ID: 27091184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome.
    Wainwright P; Byrne CD
    Int J Mol Sci; 2016 Mar; 17(3):367. PubMed ID: 26978356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NAFLD-NASH: An Under-Recognized Epidemic.
    Jennings J; Faselis C; Yao MD
    Curr Vasc Pharmacol; 2018; 16(3):209-213. PubMed ID: 28676024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.